Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study
-
Narrado por:
-
De:
On this episode of the JVRD Author's Forum podcast, Dr. David Eichenbaum of Retina Vitreous Associates of Florida discusses "Biosimilar Ranibizumab (RaniEyes) Safety and Efficacy in the Real World: BRESER Study," published in the May/June 2025 issue of JVRD.
Host Dr. Timothy Murray and Dr. Eichenbaum talk about how biosimilars are developed and approved, and why real-world data is essential for evaluating their safety and effectiveness on a large scale. Learn why cost, access, and post-market surveillance are important factors in the growing role of biosimilars in retina care.
For more information, visit www.ASRS.org/JVRDForum.
Welcome to ASRS’s Journal of Vitreoretinal Diseases (JVRD) Author’s Forum. JVRD is the official scientific peer-reviewed journal of the American Society of Retina Specialists (ASRS), offering the highest quality and most impactful research and clinical information in the field. Join host Dr. Timothy Murray, Editor-in-Chief of JVRD, as he discusses cutting-edge developments featured in JVRD with the lead authors, who share clinical pearls and explore their significance in advancing patient care.